The Speakers

SAY HELLO TO
OUR SPEAKERS

Maher Albitar, MD
Founder
Chief Executive Officer
Chief Medical Officer
Genomic Testing Cooperative
View Profile
Founder
Chief Executive Officer
Chief Medical Officer
Genomic Testing Cooperative
Dr. Albitar has extensive experience in anatomic/clinical pathology, hematopathology, and molecular pathology. He also has extensive business and administrative experience as an executive leader of large laboratories, Board member, and director of large scientific and genomic diagnostic studies. Until recently, Dr. Albitar was the Senior Vice President, Chief Medical Officer and Director of Research and Development at NeoGenomics.
He is credited with transforming the NeoGenomics Laboratories from FISH testing company to a company offering the most sophisticated molecular testing. Prior to NeoGenomics, Dr. Albitar served as the Medical Director for Hematopathology and Oncology, Nichols Institute, Quest Diagnostics, and Chief R&D for Hematopathology and Oncology for Quest Diagnostics from 2003 to 2010. From 1991 to 2003, Dr. Albitar held various faculty positions at the University of Texas MD Anderson Cancer Center, including Section Chief of Leukemia Section in Laboratory Medicine and Pathology Department, Director of the molecular laboratory and Director of Hematopathology Fellowship program.
Dr. Albitar was a tenured full professor in Pathology and Leukemia at the time of leaving MD Anderson Cancer Center. Dr. Albitar is certified AP/CP pathologist with fellowship training in Hematopathology and molecular pathology. After his training in Hematopathology, Dr. Albitar spent 4 years in Physician/Scientist training program at the University of Pennsylvania/Howard Hughes Medical Institute and the Department of Genetics. Dr. Albitar has published more than 300 peer-reviewed papers, book chapters, and review articles. He is the lead inventor on more than 50 different patents and patent applications.
Amy DeZern, MD
Associate Professor of Oncology & Medicine
Attending Physician
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Profile
Professor of Oncology and Medicine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dr. Amy DeZern is a hematologist and medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and is an Assistant Professor of Oncology and Medicine at the Johns Hopkins University School of Medicine. She received her medical degree in 2005 from the Johns Hopkins University School of Medicine and her Master in Clinical Investigation (M.H.S.) from the Johns Hopkins Bloomberg School of Public Health. She completed residency training in internal medicine as well as fellowships in medical oncology and hematology at Johns Hopkins. Dr. DeZern sees patients at the Sidney Kimmel Comprehensive Cancer Center.
Dr. DeZern’s primary clinical and research interests are focused on bone marrow failure disorders. She has expertise in the diagnosis and treatment of myelodysplastic syndromes (MDS), aplastic anemia - both inherited and acquired, paroxysmal nocturnal hemoglobinuria (PNH), and acute leukemias. She sees clinic patients weekly with these diagnoses as well as patients in need of bone marrow transplants. Dr. DeZern greatly enjoys taking care of patients with bone marrow failure and hematologic malignancies and is dedicated to improving the care and outcomes of patients with these conditions. To that end, she is an active clinical researcher who specializes in clinical studies of diagnostics and maintains a database of samples and clinical information for outcomes research in marrow failure and leukemia. She is the principal investigator of a number of clinical protocols for patients with MDS as well as a unique clinical trial treating patients with severe aplastic anemia using a specialized bone marrow transplant regimen at Johns Hopkins. Her work has resulted in multiple publications in the scientific literature and presentations at national meetings. She is also involved with the Aplastic Anemia & MDS International Foundation and serves as one of the six principal investigators for the Edward P. Evans MDS Clinical Research Consortium.
Robert Gallo, MD
Director, USF Health Virology Center; Director, Microbial Oncology Program
Tampa General Hospital Cancer Institute
View Profile
James P. Cullison Professor of Medicine, Division of Infectious Disease, Department of Internal Medicine, USF Heath
Director, USF Health Virology Institute
Director, Microbial Oncology Program, Tampa General Hospital Cancer Institute
Chairman, Scientific Leadership Board and Co-Founder, Global Virus Network
Dr. Robert C. Gallo is world-renowned for his research on HIV, most notably his co-discovery in 1984 that HIV (a retrovirus) was the cause of AIDS and his development of the HIV blood test. Previously, Gallo and fellow scientists discovered the first human retrovirus, HTLV-1, a cause of adult T cell leukemia. The discoveries of all human retroviruses (HTLV-1, HTLV-2 and HIV) were dependent on Gallo’s earlier discovery in 1976 of interleukin-2 (IL-2), a growth factor for human T cells, which enabled scientists to culture human T cells for virus isolations. IL-2 is now also used widely in all cancer cell immunotherapy. In 1986, he isolated human herpes virus 6 (HHV-6), the first new human herpes virus discovered in more than 25 years. Later, others showed HHV-6 caused Roseola. In 1996, his discovery that some natural compounds known as chemokines can block HIV was hailed by Science magazine as that year’s most important scientific breakthroughs. Gallo’s current work continues to lead groundbreaking studies in infectious diseases, cancer virology, and global health. Gallo has authored over 1,300 scientific publications as well as the book "Virus Hunting - AIDS, Cancer & the Human Retrovirus." Gallo has been awarded nearly 40 honorary doctorates and was twice recipient of the U.S. Albert Lasker Award in Medicine (1982 and 1986) and many other top honors from countries from around the world. He was the most cited scientist in the world from 1980 to 1990. Gallo is a member of the National Academy of Sciences and the Institute of Medicine. Gallo was previously at the National Cancer Institute from 1965 to 1995, co-founded and directed the Institute of Human Virology at the University of Maryland School of Medicine from 1995-2024, and co-founded and chaired the Scientific Leadership Board of the Global Virus Network since 2011 to present, prior to joining the University of South Florida to found the USF Health Virology Institute and direct the Microbial Oncology Program at the Tampa General Hospital Cancer Institute in 2024.
Mohammad Maher Abdul Hay, MD
Clinical Assistant Professor
NYU Grossman School of Medicine
View Profile
Clinical Assistant Professor
NYU Grossman School of Medicine
Dr. Mohammed Maher Abdul Hay has always been passionate about medicine and is deeply committed to providing exceptional clinical care and teaching. His decision to specialize in hematology and oncology stems from the immense breadth of the field, which continually motivates him to expand his knowledge to better serve patients with cancer.
At NYU Langone’s Perlmutter Cancer Center, Dr. Hay delivers outstanding hematological care alongside a team of talented physicians and nurses. The center offers not only conventional treatments but also access to cutting-edge therapies through numerous clinical trials for acute leukemias and myelomas.
Dr. Hay is also actively engaged in translational research, focusing on transforming scientific discoveries into practical advancements in patient care. During his postdoctoral research fellowship at the University of Illinois at Chicago, he recognized the critical role translational research plays in uncovering the intricate mechanisms of hematological and oncological diseases, paving the way for innovative treatments.
In addition to his research endeavors, Dr. Hay conducts clinical trials to make novel therapies available to patients. As a dedicated faculty member at NYU School of Medicine, he has been honored as “Teacher of the Year” in the hematology program for three consecutive years, reflecting his commitment to educating the next generation of medical professionals.
Jingmei Hsu, MD
Associate Professor
Department of Medicine
NYU Grossman School of Medicine
View Profile
Associate Professor, Department of Medicine, NYU Grossman School of Medicine
Director, Cellular Therapy Laboratory
Dr. Jingmei Hsu is a distinguished member of the hematology group at NYU Langone’s Perlmutter Cancer Center, specializing in the treatment of patients with blood cancers and other blood disorders through advanced therapies such as stem cell transplantation and CAR T-cell therapies. These innovative treatments leverage the body’s immune cells to target and destroy cancer cells effectively.
Dr. Hsu's passion for medicine was profoundly influenced by family. Her father was a pioneering researcher in herbal medicine, applying modern biochemical approaches to traditional practices, while her mother served as a dedicated family physician. This familial influence, coupled with a PhD in cell and molecular biology, inspired Dr. Hsu to pursue a medical career in hematology.
In clinical practice, Dr. Hsu is deeply committed to providing compassionate care, emphasizing the importance of a strong doctor-patient relationship. When meeting patients for the first time, Dr. Hsu takes on the role of doctor-educator, explaining complex treatments such as stem cell transplantation or CAR T-cell therapy in an approachable manner.
At NYU Langone, Dr. Hsu collaborates closely with the entire hematology group, participating in regular discussions to refine patient care strategies. The team is dedicated to identifying the most effective approaches for treating both cancerous and nonmalignant blood conditions using cellular therapies.
Dr. Hsu is also a trailblazer in research, contributing to groundbreaking advancements in cancer and HIV treatment. She performed the world’s first successful CCR5 △32/△32 stem cell transplant in a patient living with HIV and acute leukemia, achieving a potential cure for both conditions simultaneously in a woman. This monumental achievement adds to the global effort to discover a cure for HIV.
Additionally, Dr. Hsu works closely with research teams to develop and implement novel CAR T-cell therapies, ensuring these cutting-edge options are accessible to patients. Her collaboration with the stem cell transplant team focuses on innovative methods to prevent graft-versus-host disease, improving outcomes for bone marrow transplant recipients.
Dr. Hsu finds immense fulfillment in being part of patients’ journeys to fight cancer, particularly during an era of remarkable advancements that offer new hope for managing and curing a growing number of cancers.
Alan Kerr, II, MD, PhD
Hematologist-Oncologist
Physician Scientist
Tampa General Hospital
View Profile
Hematologist-Oncologist
Physician Scientist
Tampa General Hospital
Dr. D. Alan Kerr is a hematologist-oncologist and physician scientist with Tampa General Hospital, where he previously conducted continuity clinic work with a focus on malignant hematology. He specializes in benign and malignant hematology as well as solid tumor oncology.
Prior to joining Tampa General, Dr. Kerr treated patients in a private community practice at Advanced Cancer Treatment Centers (ACTC) in Brooksville, Fla., after completing a three-year hematology and medical oncology fellowship program with Moffitt Cancer Center/University of South Florida. Before that, he completed an internal medicine residency program at the University of Louisville in Kentucky, where he served as a chief medical resident. In the same department, he followed his passion for teaching future medical professionals as an assistant professor from 2015-16. Dr. Kerr received his medical degree from the University of Louisville School of Medicine and holds a Ph.D. in biochemistry and molecular biology from the University of Louisville.
Dr. Kerr is a site investigator for numerous active clinical trials and his primary clinical interests include lymphomas and myeloid diseases. Well-versed in translational research and clinical research protocols, Dr. Kerr is credited with several publications, oral presentations and abstracts on a wide range of oncology topics. He is a diplomat of the American Board of Internal Medicine and has memberships with the American Society of Clinical Oncology and the American Society of Hematology.
Jeffrey Lancet, MD
Senior Member and Chair
Department of Malignant Hematology
H Lee Moffitt Cancer Center and Research Institute
View Profile
Senior Member and Chair
Department of Malignant Hematology
H Lee Moffitt Cancer Center and Research Institute
Jeffrey E Lancet, MD, is a Senior Member and Chair of the Department of Malignant Hematology for the H Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. He is a hematologist and focuses his clinical practice in acute leukemias and myelodysplastic syndromes. He also provides consultation for other hematologic malignancies. As a clinical investigator, Dr Lancet has written, authored, and published several early phase clinical trials utilizing novel therapies for these diseases, and currently serves as the principal investigator for many ongoing trials. Within the field of acute leukemias, he has worked extensively with the National Cancer Institute (NCI) and the Southwest Oncology Group. Dr Lancet was a recipient of the NCI-ASCO Clinical Investigator Team Leadership Award in 2010.
Jonathan Licht, MD
Director
University of Florida Health Cancer Center
View Profile
Director and Marshall E. Rinker Senior Chair
University of Florida Health Cancer Center
NCI funded for 30 years, Dr. Licht is also Principal Investigator of a Leukemia and Lymphoma Society (LLS) Specialized Center of Research. He is an Associate Editor of Oncogene and serves on the editorial boards of Cancer Discovery, Cancer Cell, Cancer Research and Clinical Cancer Research. Dr. Licht is chair of the Taskforce for Hematological Malignancies of AACR, and is co-chair of the Medical/Scientific Board of the LLS. Dr. Licht has published over 200 articles, reviews and book chapters and has mentored over 40 graduate students and postdoctoral fellows and 20 faculty members. In 2021 he was the winner of the American Society of Hematology Basic Sciences Mentor Award.
Tiphaine Martin, MEg, PhD
Researcher
Icahn School of Medicine at Mount Sinai
View Profile

Researcher - Computational Biologists, Bioinformatics & Biostatistics
Icahn School of Medicine at Mount Sinai
Tiphaine has a diverse international background, with nearly 20 years of scientific research experience across France, Switzerland, the UK, Australia, and the USA. She has worked in various professional settings, including universities, research institutes, consortia, hospitals, startups, and private companies, and has contributed to interdisciplinary projects spanning biology, mathematics, computational informatics, robotics, and biochemistry. Her research has involved numerous local and international collaborations, and she has lived in different countries throughout her career.
As a leader, Tiphaine has managed teams of up to nine people in multidisciplinary environments, overseeing the development and maintenance of infrastructures and bioinformatics tools. She has employed statistical methods to address biological questions within projects such as the Génolevures consortium (e.g., annotating eight yeast genomes), the GRISBI project (e.g., developing grids for the bioinformatics community), as well as during her Ph.D. and postdoctoral work. Over the past decade, she has focused on investigating the associations between biomarkers and disease status, particularly in complex diseases and cancer, and has explored interactions within large multi-omics datasets and electronic health records (EHR) from extensive cohorts.
Manja Meggendorfer, PhD
Head
Molecular Genetics
Munich Leukemia Laboratory
View Profile
Head, Molecular Genetics
Munich Leukemia Laboratory (MLL)
Manja Meggendorfer is the Head of Molecular Genetics at Munich Leukemia Laboratory (MLL), where she oversees various R&D activities such as the 5,000 genome project, which is aimed at better understanding the genetic factors behind leukemia. She received her Master of Science in Biology from the Ludwig-Maximilians-University in Munich and her PhD. in collaboration with the Helmholtz Center Munich working on gene regulation within the architecture of the cell nucleus. After her post-doctorate, she moved to the field of hematology as a scientist in the department of molecular genetics at MLL. In combination with her MBA in Health Care Management, Manja hopes to improve the diagnostic and prognostic work associated with routine diagnostic approaches for leukemia or lymphoma patients.
Stephen Nimer, MD
Director
Sylvester Comprehensive Cancer Center
View Profile

Director, Sylvester Comprehensive Cancer Center
Oscar de la Renta Endowed Chair in Cancer Research
Professor of Medicine, Biochemistry and Molecular Biology
Executive Dean for Research, Miller School of Medicine
Secondary Appointment of Biochemistry and Molecular Biology
Professor of Chemical, Environmental & Materials Engineering
Miller School of Medicine, University of Miami
Stephen D. Nimer, M.D., is the director of the National Cancer Institute (NCI)-designated Sylvester Comprehensive Cancer Center. He is also the executive dean for research and a professor of medicine, biochemistry and molecular biology at the University of Miami Miller School of Medicine. Dr. Nimer's career spans more than 30 years in clinical care, research, administration and leadership.
Before joining the Miller School of Medicine in 2012, Dr. Nimer held several positions at Memorial Sloan-Kettering Cancer Center for almost 20 years. There, he served as the Alfred P. Sloan Chair in Cancer Research, head of the division of hematologic oncology, vice chairman for faculty development and chief of the Hematology Service. Under Dr. Nimer's leadership, Sylvester Comprehensive Cancer Center, which serves more than six million people in its catchment area and sits at the “gateway” to the Caribbean and Latin America, became an NCI-designated center in July 2019. It is the only NCI-designated cancer center in South Florida and the second youngest among all NCI-designated cancer centers. In 2022, U.S. News & World Report recognized Sylvester as a top-ranked cancer hospital in the nation. As a member of the University of Miami’s Diversity Task Forces and the American Society of Hematology, Diversity, Equity, and Inclusion subcommittee since 2021, Dr. Nimer underscores the value of Sylvester, which offers a location with unparalleled diversity — a veritable microcosm of what U.S. demographics are projected to be in 50+ years. Dr. Nimer leads Sylvester’s research and experience with diverse community partnerships to create model approaches that address challenges and generate opportunities—all to prepare the cancer center for the future. Dr. Nimer shares this unique perspective through his service on external advisory boards for several NCI-designated cancer centers.Through key engagements and on-site advocacy, Dr. Nimer ensures cancer research remains at the forefront of efforts at the state and federal levels in contributing to meaningful cancer-related policies, innovative community care models and funding priorities. Since 2018 he has been a member of the Association of American Cancer Institutes, Nominating Committee and in 2020, he became a member of the Science Policy and Government Affairs Committee (SPGAC) of the American Association for Cancer Research.
Throughout his career, Dr. Nimer has cared for patients with myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), multiple myeloma and lymphoma and has decades of service to non-profits in their efforts to advance patient science and clinical care. He has chaired foundations including the MDS Foundation, the Leukemia & Lymphoma Society and the AAMDSIF. Moreover, he is the chairman of the Gabrielle’s Angel Foundation and Myelodysplastic Syndromes Foundation (MDSF), two organizations that award funding for early and senior career investigators, where Dr. Nimer performs oversight including grant reviews and convening board meetings.
Outside of his committee and foundation duties, Dr. Nimer has been continuously funded by the NIH for three decades and has served as PI on Leukemia and Lymphoma Society multi-project Specialized Center of Research awards. In his lab, Dr. Nimer focuses on understanding the genes involved in the development and progression of MDS and AML to identify novel therapeutic approaches to make hematologic cancers more responsive to treatment. Dr. Nimer holds two patents for the treatment of leukemia.
A physician-scientist in the field of hematology-oncology and cancer research, Dr. Nimer has authored more than 300 scientific publications and holds numerous awards including the Oscar de La Renta Endowed Chair in Cancer Research, the Irma T. Hirschl Career Scientist Award and he received the E. Donnall Thomas Award in 2015 from the Bone Marrow Foundation. In April 2021, the Academy of Science, Engineering and Medicine of Florida inducted Dr. Nimer to recognize his outstanding contributions to the scientific community. Similarly, the American Society of Clinical Investigators and the Association of American Physicians elected him to highlight his influential role in shaping the field of oncology. Dr. Nimer is also a Fellow of the American College of Physicians, further demonstrating his dedication to patient care and clinical excellence.
Gustavo Rivero, MD
Director, Translational Research for Hematologic Malignancies
Tampa General Hospital Cancer Institute
View Profile
Director
Translational Research for Hematologic Malignancies
Tampa General Hospital Cancer Institute
Dr. Rivero is a hematologist oncologist and translational scientist at Tampa General Hospital. Prior to joining Tampa General, he served as an associate professor in hematology and oncology at Baylor College of Medicine and Georgetown University School of Medicine. A distinguished translational scientist, Dr. Rivero focuses on advancing treatments for myeloid malignancies, including Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myeloproliferative Neoplasms (MPN).
Dr. Rivero’s research is not just about understanding the mechanisms that initiate leukemia, but also about pushing the boundaries of what is possible. His recent discovery of a novel age-related nucleotide modification prevalent in AML is a testament to his commitment to innovation. Dr. Rivero’s team is also investigating how leukemia induces immunogenicity to develop innovative cellular and vaccine-based treatments to prevent and combat these disorders.
Dr. Rivero completed his advanced training in hematology and oncology at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH) in Bethesda, Maryland.
His board certifications include Internal Medicine and Hematology. He earned his medical degree from Francisco de Miranda University in Coro, Venezuela, and completed his internship and residency at J. Stroger Hospital of Cook County in Chicago, Illinois.
Anne Renteria, MD
Site Director, Transplantation & Cellular Therapy Program at Perlmutter Cancer Center
NYU Langone Health
View Profile
Sergio Rutella, MD, PhD
Professor of Cancer Immunotherapy
Nottingham Trent University
View Profile
Professor of Cancer Immunotherapy
Director of the John van Geest Cancer Research Centre
College of Science and Technology
Nottingham Trent University
Professor Sergio Rutella, MD PhD, is a licensed haematologist and Fellow of the Royal College of Pathologists (FRCPath). He received NTU’s Vice Chancellor’s Outstanding Researcher Award in 2019 and has been elected as a Fellow by the Royal Society of Biology on 1 April 2022 for "Haematology work and impact on the Biosciences".
Professor Rutella is the current Director of Nottingham Trent University's John van Geest Cancer Research Centre. His academic career has been predicated on the bench-to-bedside-to-bench paradigm in Haematology. Over the last 30 years, Professor Rutella has been engaged in clinical and translational research focusing on immunotherapy approaches to improve the outcome of haematological malignancies, with an emphasis on antibody-based therapeutics and haematopoietic stem cell processing and transplantation. He has an extensive track record of leading studies that involve a strong correlative component and collaborating with other investigators, both basic and clinical.
At Nottingham Trent University, Professor Rutella’s translational research program focuses on deciphering the immune ecosystem of haematological malignancies, on visualising the state of cancer-immune interactions in individual patients and on biomarker discovery, with the aim to bring rational immunotherapy approaches to the clinic, guide treatment choices and minimise toxicity. The research group nurtures the ambition to help design immunotherapy clinical trials that select cancer patients based on immune states and markers, and to test whether this strategy increases the rate of durable responses.
During his academic career, Professor Rutella has authored and co-authored 230 full-length, peer-reviewed publications (H-index = 65; i10-index = 191; times cited > 14,800; total impact factor > 2,050) and 13 book chapters, and has secured > £12M of research funding as principal investigator/co-investigator. His teaching contributions are made to Bachelors and Masters projects on the BIOL40111 MSc Research Project module, the BIOL40102 "Research Methods and Bioethics" module, and the BIOL33171 "Immunology and Virology" module.
Professor Rutella has led a REF2021 Impact Case Study entitled: ‘Improving the Management and Survival of Patients with Aggressive, Treatment-Resistant Cancers’ (https://www.ntu.ac.uk/research/impact-case-studies/ref-2021/improving-the-management-and-survival-of-patients-with-aggressive,-treatment-resistant-cancers).
David Sallman, MD
Leukemia and Myelodysplastic Syndrome (MDS) Section Head
H. Lee Moffitt Cancer Center & Research Institute
View Profile
Leukemia and Myelodysplastic Syndrome (MDS) Section Head Associate Member, Department of Malignant Hematology H. Lee Moffitt Cancer Center & Research Institute
Associate Professor, Department of Oncologic Sciences University of South Florida
Tampa, FL
David Sallman, MD, is an associate member in the Department of Malignant Hematology at Moffitt Cancer Center and associate professor in the Department of Oncologic Sciences at the University of South Florida, both in Tampa. Dr. Sallman is the myeloid section head of the malignant hematology department. He earned his medical degree from the University of South Florida College of Medicine and completed an internal medicine residency at Massachusetts General Hospital before completing a hematology/oncology fellowship at Moffitt Cancer Center. He is board certified in medical oncology, hematology, and internal medicine.
Dr Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and myeloproliferative neoplasms. His research interests focus on the development of novel targeted therapeutic strategies (phase 1 and 2 clinical trials) for patients with MDS and AML, based on the underlying mutational drivers of each disease. Specifically, he studies the genetic drivers of myeloid diseases to improve prognostication for patients and to allow for more personalized treatment. He has published significantly on this topic, including recently in highly regarded journals such as Leukemia and Haematologica, and these works are the foundation of clinical trials/translational studies designed to improve the quality of life and survival of patients with MDS. He is the principal investigator for multiple ongoing studies focused on higher-risk MDS. Furthermore, his recent work has focused on TP53-mutant MDS, where he and his team identified and validated that the clonal burden of TP53 mutation is strongly concordant with patient outcomes and are intimately tied with the clinical trajectory of these patients. Additionally, they have identified that serial next-generation sequencing has significant prognostic value and can be an early biomarker of outcome with novel agents. He has been the lead principal investigator (PI) for phase 1-3 trials TP53-mutant MDS and AML patients. Additionally, Dr. Sallman serves as lead PI for multiple cellular therapy trials including CAR-T and TCR therapies.
Dr Sallman has authored and coauthored numerous articles, books, book chapters, and abstracts, and serves as reviewer for multiple journals. He received the Young Investigator Grant from the MDS Foundation in 2017 and the Dresner Foundation Career Development award in 2018.
Nikesh Shah, MD
Hematologist-Oncologist
Tampa General Hospital Cancer Institute
View Profile
Hematologist/Oncologist
Tampa General Hospital Cancer Institute
Dr. Nikesh Shah is a hematologist/oncologist at Tampa General Hospital who specializes in hematologic malignancies, particularly lymphomas. Prior to joining Tampa General, Dr. Shah served as a chief fellow for the hematology/oncology fellowship program at Moffitt Cancer Center and the University of South Florida in Tampa. He completed the J. Willis Hurst Internal Medicine Residency Program at Emory University School of Medicine in Atlanta after receiving his medical degree from the University of Miami Leonard M. Miller School of Medicine in Miami, FL.
Dr. Shah is dedicated to developing close relationships with his patients and their families, providing them with a full understanding of each disease and determining the best personalized care for each patient. He enjoys conducting clinical research to identify the most cutting-edge treatment options available and has been credited with several peer-reviewed publications, presentations, abstracts, and book chapters in areas of his expertise.
Dr. Shah has memberships with the American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, Florida Society of Clinical Oncology and the Florida Medical Association.
Iberia Romina Sosa, MD
Associate Professor
Chief, Division of Hematology
Fox Chase Cancer Center
View Profile
David Swoboda, MD
Clinical Director of Leukemia Program
Tampa General Hospital Cancer Institute
View Profile
Clinical Director
Leukemia Program
Tampa General Hospital Cancer Institute
Dr. David Swoboda is a hematologist oncologist at Tampa General Hospital who specializes in malignant hematology. Prior to joining Tampa General, he was a chief hematology-oncology fellow at H. Lee Moffitt Cancer Center in Tampa after serving as a chief resident at Medstar Georgetown University Hospital in Washington, D.C. Dr. Swoboda received his medical degree from Florida State University College of Medicine in Tallahassee, where he was the president of the Internal Medicine Interest Group.
Dr. Swoboda enjoys developing a close relationship with his patients and their families, building trust and gaining a full understanding of each disease in order to provide personalized, comprehensive care. His research is directed toward acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative disorders. He has published several entries in peer-reviewed journals and has participated in numerous scientific abstract presentations. Dr. Swoboda has memberships with the Society for Hematology Oncology, American Society of Hematology and American Society of Clinical Oncology.
Olga Timofeeva, PhD
Associate Director
UCLA Immunogenetics Center
View Profile